Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index; 82 of the 214 sources its claims cite were checked for support.

GLP-1 and the Neurobiology of Eating Control: Recent Advances

Open access
Jones, Lauren A, Brierley, Daniel I · 2025 · Endocrinology

Abstract

Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy intake, and most successful anti-obesity medications (AOMs) counter this positive energy balance through the suppression of eating to drive weight loss. Historically, AOMs have been characterized by modest weight loss and side effects which are compliance-limiting, and in some cases life-threatening. However, the field of obesity pharmacotherapy has now entered a new era of AOMs based on analogues of the gut hormone and neuropeptide glucagon-like peptide-1 (GLP-1). The latest versions of these drugs elicit unprecedented levels of weight loss in clinical trials, which are now starting to be substantiated in real-world usage. Notably, these drugs reduce weight primarily by reducing energy intake, via activation of the GLP-1 receptor on multiple sites of action primarily in the central nervous system, although the most relevant sites of action, and the neural circuits recruited remain contentious. Here we provide a targeted synthesis of recent developments in the field of GLP-1 neurobiology, highlighting studies which have advanced our understanding of how GLP-1 signaling modulates eating, and identify open questions and future challenges we believe still need to be addressed to aid the prevention and/or treatment of obesity.

Overview

CoChat Summary

TL;DR

This review synthesizes recent advances in GLP-1 neurobiology and obesity pharmacotherapy, arguing that GLP-1-based anti-obesity medications reduce eating mainly through CNS GLP-1R populations while endogenous peripheral and central GLP-1 systems are functionally separable. It highlights unresolved questions about the sites of action, nausea versus satiety circuits, real-world efficacy, and weight regain.

Key findings

  • GLP-1-based AOMs reduce weight primarily by lowering energy intake via GLP-1R activation, mainly in the CNS; semaglutide achieved up to 15% weight loss in trials, while tirzepatide and retatrutide achieved placebo-subtracted weight loss of ≥20%, and CagriSema ∼15% in shorter-term phase 1/2 trials.
  • Endogenous gut-derived GLP-1 contributes to satiation mainly through peripheral vagal afferents in the hepatic portal vein and intestinal mucosa, and via the ileal brake circuit; central NTS preproglucagon neurons mediate physiological satiation and stress-induced hypophagia but are not required for liraglutide or semaglutide anorectic effects.
  • Recent rodent studies implicate multiple CNS GLP-1R populations in GLP-1RA effects, including the area postrema/NTS, locus coeruleus, hypothalamic arcuate and dorsomedial nuclei, and lateral septum; area postrema GLP-1R neurons may drive nausea, whereas NTS populations may mediate satiety, and tirzepatide’s lower discontinuation-inducing GI events may involve GIPR-expressing GABAergic area postrema neurons.
  • Clinical limitations remain: real-world semaglutide weight loss ranges from 4% to 5% in one study to 13.4% in another; SELECT reported 8.7% placebo-subtracted weight loss at 4 years versus 12.5% in STEP 1 at 68 weeks; 10% to 15% of STEP/SURMOUNT participants were nonresponders, 32% in SELECT, and 19% in a real-world setting; GI side effects affect 50% to 60%, with discontinuation in 4% to 10%, and 50% to 65% of lost weight is regained up to a year after semaglutide or tirzepatide cessation.

Methods

  • Targeted narrative synthesis of recent developments in GLP-1 neurobiology relevant to obesity, highlighting studies on how GLP-1 signaling modulates eating and identifying open questions for GLP-1-based AOMs.
  • Includes discussion of rodent mechanistic studies and a table summarizing key body weight loss efficacy from clinical trials versus real-world studies of GLP-1RAs licensed for obesity.
  • No primary experimental data, systematic search strategy, or meta-analytic methods are reported.

Limitations

  • The paper states that the most relevant sites of action and neural circuits recruited by GLP-1RAs remain contentious, and that many mechanistic insights come from rodent studies.
  • It notes that real-world effectiveness data are conflicting and that clinical trials tend to overestimate weight loss, with limited long-term data for newer GLP-1RA-based combination therapies.
  • Evident from the text: as a narrative review, it does not report a systematic search strategy or formal risk-of-bias assessment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/endocr/bqae167

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Gut-brain pathways and sites of action of endogenous and exogenous GLP-1 signaling. A, Schematic overview of the neuronal and hormonal/pharmacological pathways by which endogenous GLP-1 and GLP-1-based AOMs convey anorectic signals to the brain. Under physiological conditions, proximal L-cells in the upper small intestine release GLP-1 in response to ingested nutrients, signaling via paracrine and endocrine routes (blue) to act on GLP-1 receptors on chemosensory vagal afferent in intestinal villi and the hepatic portal vein (HPV), and on gut-innervating mechanosensory vagal afferents. Under supraphysiological conditions, for example, after exceptionally large and/or nutrient-dense meals, GLP-1 from L-cells may also reach sufficiently high systemic concentrations to act directly on the brain, via neuronal GLP-1 receptors in circumventricular organs such as the area postrema. Undigested nutrients reaching the ileum can trigger GLP-1 release from distal L-cells to trigger the multisynaptic gut-brain circuit (orange) comprising the ileal brake. Peripherally administered GLP-1-based AOMs reach steady-state systemic concentrations orders of magnitude higher than endogenous GLP-1, reaching and acting primarily on circumventricular organs in the CNS (magenta). AOMs also presumably bind all peripheral sites of action of endogenous GLP-1, but these pathways may be dispensable for AOM effects on eating and body weight. B, Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54). (Created in BioRender. Brierley, D. (2024) BioRender.com/d09h242).
Figure 1. Gut-brain pathways and sites of action of endogenous and exogenous GLP-1 signaling. A, Schematic overview of the neuronal and hormonal/pharmacological pathways by which endogenous GLP-1 and GLP-1-based AOMs convey anorectic signals to the brain. Under physiological conditions, proximal L-cells in the upper small intestine release GLP-1 in response to ingested nutrients, signaling via paracrine and endocrine routes (blue) to act on GLP-1 receptors on chemosensory vagal afferent in intestinal villi and the hepatic portal vein (HPV), and on gut-innervating mechanosensory vagal afferents. Under supraphysiological conditions, for example, after exceptionally large and/or nutrient-dense meals, GLP-1 from L-cells may also reach sufficiently high systemic concentrations to act directly on the brain, via neuronal GLP-1 receptors in circumventricular organs such as the area postrema. Undigested nutrients reaching the ileum can trigger GLP-1 release from distal L-cells to trigger the multisynaptic gut-brain circuit (orange) comprising the ileal brake. Peripherally administered GLP-1-based AOMs reach steady-state systemic concentrations orders of magnitude higher than endogenous GLP-1, reaching and acting primarily on circumventricular organs in the CNS (magenta). AOMs also presumably bind all peripheral sites of action of endogenous GLP-1, but these pathways may be dispensable for AOM effects on eating and body weight. B, Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54). (Created in BioRender. Brierley, D. (2024) BioRender.com/d09h242).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

29 Valid · 5 Not valid · 59 Not checked · 10 Own results and interpretations

46 more claims · 12 with their cited sources checked

Create a free account to see all 103 claims and to verify the 132 references still open.

See all claims — free account
  • It may state two separate claims as one. 48
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 137 references

Research works printed but not linked: 2

  1. Novo Nordisk A/S, Wegovy: Summary of Product Characteristics
  2. NICE, 2023, Semaglutide for Managing Overweight and Obesity

Cited by

See all 43

Metadata

Authors
Jones, L. A., & Brierley, D. I.
Affiliations
University College London (GB)
Corresponding author
Brierley, Daniel I
Venue
Endocrinology
Published
2025-01-06
Volume
166
Issue
2
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W4406419586
Cited by
43
References
137
Citations by year
2026: 29 · 2025: 14
FWCI
2.39
Type
journal article
Language
en
Open access
Locations
  • Endocrinology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by-nc-nd)
Funders
Wellcome Trust (223279/Z/21/Z)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
glucagon-like peptide-1, GLP-1 receptor, obesity pharmacotherapy, anti-obesity drugs, food intake regulation, energy intake, central nervous system, neural circuits, gastrointestinal hormones, weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Appetite Regulation, Eating, Humans, Obesity, Signal Transduction, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 and the Neurobiology of Eating Control: Recent Advances. https://app.cochat.ai/papers/10.1210/endocr/bqae167
The paper
Jones, L. A., & Brierley, D. I. (2025). GLP-1 and the Neurobiology of Eating Control: Recent Advances. Endocrinology. https://doi.org/10.1210/endocr/bqae167

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.